{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoadjuvant+Therapy",
    "query": {
      "condition": "Neoadjuvant Therapy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1399,
    "total_pages": 140,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoadjuvant+Therapy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T17:16:20.798Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01369329",
      "title": "A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease",
        "IBD",
        "Colitis",
        "Inflammatory Bowel Disease"
      ],
      "interventions": [
        {
          "name": "Group 2 ustekinumab 130 mg",
          "type": "DRUG"
        },
        {
          "name": "Group 3: ustekinumab approximately 6 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Group 1: Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 769,
      "start_date": "2011-07",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2016-12-07",
      "last_synced_at": "2026-07-22T17:16:20.798Z",
      "location_count": 67,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01369329"
    },
    {
      "nct_id": "NCT02517502",
      "title": "Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cognitive Dysfunction"
      ],
      "interventions": [
        {
          "name": "DHA",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Carol Fabian, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2015-07",
      "completion_date": "2019-05-03",
      "has_results": false,
      "last_update_posted_date": "2022-01-24",
      "last_synced_at": "2026-07-22T17:16:20.798Z",
      "location_count": 2,
      "location_summary": "Decatur, Illinois • Kansas City, Kansas",
      "locations": [
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02517502"
    },
    {
      "nct_id": "NCT02945579",
      "title": "Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Estrogen Receptor Negative",
        "HER2 Positive Breast Carcinoma",
        "HER2/Neu Negative",
        "Invasive Breast Carcinoma",
        "Progesterone Receptor Negative",
        "Stage I Breast Cancer AJCC v7",
        "Stage IA Breast Cancer AJCC v7",
        "Stage IB Breast Cancer AJCC v7",
        "Stage II Breast Cancer AJCC v6 and v7",
        "Stage IIA Breast Cancer AJCC v6 and v7",
        "Stage IIB Breast Cancer AJCC v6 and v7",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Undergo EBRT",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Partial Breast Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "30 Years and older · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2017-01-20",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-07-22T17:16:20.798Z",
      "location_count": 8,
      "location_summary": "Gilbert, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Voorhees Township",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02945579"
    },
    {
      "nct_id": "NCT00526656",
      "title": "Sunitinib in Treating Patients With Locally Advanced Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2007-09",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-07-22T17:16:20.798Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00526656"
    },
    {
      "nct_id": "NCT06320717",
      "title": "AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Blood sample",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-01-02",
      "completion_date": "2026-07-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-07-22T17:16:20.798Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • West Islip, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "West Islip",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06320717"
    },
    {
      "nct_id": "NCT02689427",
      "title": "Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Breast Carcinoma",
        "Stage I Breast Cancer AJCC v7",
        "Stage IA Breast Cancer AJCC v7",
        "Stage IB Breast Cancer AJCC v7",
        "Stage II Breast Cancer AJCC v6 and v7",
        "Stage IIA Breast Cancer AJCC v6 and v7",
        "Stage IIB Breast Cancer AJCC v6 and v7",
        "Stage III Breast Cancer AJCC v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Axillary Lymph Node Dissection",
          "type": "PROCEDURE"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lymph Node Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2016-09-22",
      "completion_date": "2023-11-15",
      "has_results": true,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-07-22T17:16:20.798Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02689427"
    },
    {
      "nct_id": "NCT03943173",
      "title": "Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "BRCA-Mutated Ovarian Carcinoma",
        "BRCA1 Gene Mutation",
        "BRCA2 Gene Mutation",
        "High Grade Fallopian Tube Serous Adenocarcinoma",
        "High Grade Ovarian Serous Adenocarcinoma",
        "Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Stage III Fallopian Tube Cancer AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Primary Peritoneal Cancer AJCC v8",
        "Stage IIIA Fallopian Tube Cancer AJCC v8",
        "Stage IIIA Ovarian Cancer AJCC v8",
        "Stage IIIA Primary Peritoneal Cancer AJCC v8",
        "Stage IIIA1 Fallopian Tube Cancer AJCC v8",
        "Stage IIIA1 Ovarian Cancer AJCC v8",
        "Stage IIIA2 Fallopian Tube Cancer AJCC v8",
        "Stage IIIA2 Ovarian Cancer AJCC v8",
        "Stage IIIB Fallopian Tube Cancer AJCC v8",
        "Stage IIIB Ovarian Cancer AJCC v8",
        "Stage IIIB Primary Peritoneal Cancer AJCC v8",
        "Stage IIIC Fallopian Tube Cancer AJCC v8",
        "Stage IIIC Ovarian Cancer AJCC v8",
        "Stage IIIC Primary Peritoneal Cancer AJCC v8",
        "Stage IV Fallopian Tube Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Primary Peritoneal Cancer AJCC v8",
        "Stage IVA Fallopian Tube Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Primary Peritoneal Cancer AJCC v8",
        "Stage IVB Fallopian Tube Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Primary Peritoneal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2019-06-07",
      "completion_date": "2027-06-27",
      "has_results": false,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-07-22T17:16:20.798Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03943173"
    },
    {
      "nct_id": "NCT05302570",
      "title": "Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retroperitoneal Sarcoma"
      ],
      "interventions": [
        {
          "name": "Hypofractionated Proton Beam Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-12",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2022-12-15",
      "last_synced_at": "2026-07-22T17:16:20.798Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05302570"
    },
    {
      "nct_id": "NCT06529302",
      "title": "The OPBC-07/microNAC Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University Hospital, Basel, Switzerland",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 2000,
      "start_date": "2024-05-15",
      "completion_date": "2025-06",
      "has_results": false,
      "last_update_posted_date": "2025-01-24",
      "last_synced_at": "2026-07-22T17:16:20.798Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06529302"
    },
    {
      "nct_id": "NCT05535023",
      "title": "Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma",
        "Oropharynx Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "SAR444245",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-08-24",
      "completion_date": "2023-07-25",
      "has_results": false,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-07-22T17:16:20.798Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05535023"
    }
  ]
}